IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Southren, A. L.
Right arrow Articles by Weinstein, B. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Southren, A. L.
Right arrow Articles by Weinstein, B. I.

Investigative Ophthalmology & Visual Science, Vol 28, 901-903, Copyright © 1987 by Association for Research in Vision and Ophthalmology

ARTICLES AND REPORTS

Intraocular hypotensive effect of a topically applied cortisol metabolite: 3 alpha, 5 beta-tetrahydrocortisol

AL Southren, D l'Hommedieu, GG Gordon and BI Weinstein

3 alpha, 5 beta-tetrahydrocortisol, previously considered an inactive metabolite of cortisol, was found to lower significantly the intraocular pressure (IOP) of rabbits made ocular hypertensive with dexamethasone alone or with threshold levels of dexamethasone plus 5 beta-dihydrocortisol. The ocular hypotensive effect appeared within 3-7 days after the metabolite was started and persisted through the duration of the experiments. The metabolite did not lower the IOP of ocular normotensive untreated animals. Thus, 3 alpha,5 beta- tetrahydrocortisol is a naturally occurring steroid antagonist, which may be of use in the treatment of primary open-angle glaucoma.


This article has been cited by other articles:


Home page
 QJMHome page
S. Rauz, C.M.G. Cheung, P.J. Wood, M. Coca-Prados, E.A. Walker, P.I. Murray, and P.M. Stewart
Inhibition of 11{beta}-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension
QJM, July 1, 2003; 96(7): 481 - 490.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
W. R. Lo, L. L. Rowlette, M. Caballero, P. Yang, M. R. Hernandez, and T. Borras
Tissue Differential Microarray Analysis of Dexamethasone Induction Reveals Potential Mechanisms of Steroid Glaucoma
Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 473 - 485.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
T. M. Penning
Molecular Endocrinology of Hydroxysteroid Dehydrogenases
Endocr. Rev., June 1, 1997; 18(3): 281 - 305.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the Association for Research in Vision and Ophthalmology